Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHI
2601
DELISTED
Baker Hughes
BHI
| $883K | ﹤0.01% |
16,200
-340,740
| -95% | -$19.6M |
|
|
EBTC
2602
DELISTED
Enterprise Bancorp
EBTC
| $881K | ﹤0.01% |
24,800
-5,862
| -19% | -$195K |
|
|
SBB
2603
DELISTED
SUSSEX BANCORP
SBB
| $875K | ﹤0.01% |
35,950
+25,589
| +247% | +$623K |
|
|
AVID
2604
DELISTED
Avid Technology Inc
AVID
| $873K | ﹤0.01% |
+165,907
| New | +$854K |
|
|
AVX
2605
DELISTED
AVX Corporation
AVX
| $871K | ﹤0.01% |
53,300
-169,100
| -76% | -$2.79M |
|
|
EEI
2606
DELISTED
Ecology and Environment
EEI
| $871K | ﹤0.01% |
69,374
+10,274
| +17% | +$116K |
|
2607
Fulton Financial
FULT
$4.69B
| $869K | ﹤0.01% |
+45,739
| New | +$832K |
|
|
IRS
2608
IRSA Inversiones y Representaciones
IRS
$1.24B
| $863K | ﹤0.01% |
37,169
-499
| -1% | -$11.9K |
|
|
ERF
2609
DELISTED
Enerplus Corporation
ERF
| $863K | ﹤0.01% |
106,346
+40,289
| +61% | +$318K |
|
2610
Celldex Therapeutics
CLDX
$3.52B
| $861K | ﹤0.01% |
23,241
-90,621
| -80% | -$4.01M |
|
|
GZT
2611
DELISTED
Gazit-globe Ltd
GZT
| $861K | ﹤0.01% |
88,000
+4,200
| +5% | +$42.3K |
|
|
AIOT
2612
PowerFleet Inc
AIOT
$421M
| $857K | ﹤0.01% |
139,815
-33,800
| -19% | -$215K |
|
2613
Asbury Automotive
ABG
$3.76B
| $854K | ﹤0.01% |
+15,100
| New | +$868K |
|
2614
ACNB Corp
ACNB
$656M
| $854K | ﹤0.01% |
27,995
+7,056
| +34% | +$210K |
|
|
ONVI
2615
DELISTED
Onvia, Inc.
ONVI
| $854K | ﹤0.01% |
194,000
+1,200
| +0.6% | +$5.39K |
|
|
BGG
2616
DELISTED
Briggs & Stratton Corp.
BGG
| $851K | ﹤0.01% |
+35,300
| New | +$836K |
|
|
HTZ
2617
DELISTED
Hertz Global Holdings, Inc.
HTZ
| $850K | ﹤0.01% |
+85,059
| New | +$915K |
|
|
SHOS
2618
DELISTED
Sears Hometown and Outlet Stores, Inc.
SHOS
| $850K | ﹤0.01% |
314,900
+21,000
| +7% | +$66.7K |
|
2619
Pacira BioSciences
PCRX
$924M
| $849K | ﹤0.01% |
+17,800
| New | +$826K |
|
2620
Resources Connection
RGP
$144M
| $849K | ﹤0.01% |
62,000
-20,800
| -25% | -$283K |
|
|
GENE
2621
DELISTED
Genetic Technologies Ltd.
GENE
| $849K | ﹤0.01% |
47,109
+5,240
| +13% | +$110K |
|
2622
Weyco Group
WEYS
$446M
| $848K | ﹤0.01% |
30,400
+3,000
| +11% | +$83.2K |
|
2623
NRG Energy
NRG
$25.2B
| $847K | ﹤0.01% |
49,200
-1,216,116
| -96% | -$20.4M |
|
2624
State Street SPDR S&P Metals & Mining ETF
XME
$4.46B
| $842K | ﹤0.01% |
+28,100
| New | +$828K |
|
2625
NBT Bancorp
NBTB
$2.78B
| $839K | ﹤0.01% |
22,700
-23,200
| -51% | -$861K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.